1-Jahres-Chart (nicht börsennotiert)
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| THESEUS PHARMACEUTICALS Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORUKA THERAPEUTICS | 7,700 | +7,69 % | Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Preclinical Data for ORKA-002 at the 2025 American Academy of Dermatology Annual Meeting | Half-life in non-human primates (NHP) of more than 30 days, over three times longer than bimekizumab and expected to support a dose interval of two to three times per year Equivalent potency to bimekizumab... ► Artikel lesen | |
| PALVELLA THERAPEUTICS | 22,000 | +1,85 % | Palvella Therapeutics Inc.: Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update | Upon close of merger and $78.9mm concurrent private placement from a syndicate of leading healthcare-dedicated investors, completed transformation to a publicly traded rare disease biopharmaceutical... ► Artikel lesen | |
| DIANTHUS THERAPEUTICS | 15,200 | -0,65 % | Dianthus Therapeutics, Inc.: Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results | Phase 2 MaGic trial of DNTH103 in generalized Myasthenia Gravis (gMG) ongoing; top-line results on track for 2H'25 Phase 3 CAPTIVATE trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy... ► Artikel lesen | |
| LENZ THERAPEUTICS | 21,070 | -8,39 % | LENZ Therapeutics files to sell 13M shares of common stock for holders | ||
| TOURMALINE BIO | 12,830 | -2,21 % | Tourmaline Bio, Inc.: Tourmaline Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights | - Phase 2 TRANQUILITY trial in patients with elevated high-sensitivity C-reactive protein and chronic kidney disease over-enrolled to 143 total participants, on track to report topline data in the... ► Artikel lesen | |
| SPYRE THERAPEUTICS | 12,400 | -8,82 % | Spyre Therapeutics, Inc.: Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody | Preclinical data demonstrates that SPY003 is highly potent and has potential forquarterly or biannual dosing, suggesting opportunity for improved efficacy andconvenience... ► Artikel lesen | |
| QIAGEN | 35,330 | -2,40 % | Biotech Report: Kursgewinne bei Evotec und Qiagen | (shareribs.com) Frankfurt / New York 01.04.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend fester. Hierzulande legen unter anderem Biontech und Evotec zu. An der Wall Street sind die... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,010 | -7,40 % | ADMA Biologics, Inc.: ADMA Biologics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | FY 2024 Total Revenue of $426.5 Million, a 65% YoY Increase FY 2024 GAAP Net Income of $197.7 Million, Including an $84.3 Million Valuation Allowance Tax Benefit FY 2024 Adjusted EBITDA(1)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 15,270 | -7,23 % | Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard | ||
| ARS PHARMACEUTICALS | 12,800 | -4,58 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates | $7.3 million in total neffy® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024 neffy 1 mg approved by U.S. FDA for children aged four and older and weighing... ► Artikel lesen | |
| TEMPUS AI | 42,550 | -7,84 % | Tempus AI, Inc. (TEM): Among Stocks That Will Profit From AI | ||
| BIONTECH | 80,50 | -3,77 % | BioNTech-Aktie: Sie haben keine Ahnung! | News von Trading-Treff.de Für BioNTech ist aktuell der Trend nach unten gerichtet. Auch am Freitag ging es um über 1,2 % abwärts. Die Aktie war in den vergangenen Wochen schon der Katastrophe nahe.... ► Artikel lesen | |
| EVOTEC | 5,515 | -6,53 % | Evotec Aktie: Unruhen drohen! | News von Trading-Treff.de Die Evotec SE kämpft derzeit mit erheblichen Kursverlusten. Mit einem aktuellen Schlusskurs von 6,00 Euro verzeichnete das Papier am Freitag einen Rückgang von 1,88 Prozent.... ► Artikel lesen | |
| JANUX THERAPEUTICS | 25,770 | -4,59 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| STRYKER | 316,00 | -0,06 % | Dividendenbekanntmachungen (31.03.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1847 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,187 EUR ADVANCED FLOWER CAPITAL... ► Artikel lesen |
Das Unternehmen THESEUS PHARMACEUTICALS INC kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu THESEUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
